Global Dry Eye Syndrome Market Growth 2025-2031
The global Dry Eye Syndrome market size is predicted to grow from US$ 5749 million in 2025 to US$ 7559 million in 2031; it is expected to grow at a CAGR of 4.7% from 2025 to 2031.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
In this report, we mainly study the drugs and eye drops for dry eye.
Global Dry Eye Syndrome key players include Allergan, Alcon, Novartis, Santen Pharma, Johnson & Johnson, etc. Global top five manufacturers hold a share over 60%.
North America is the largest market, with a share over 55%, followed by Europe and Asia-Pacific, both have a share over 35 percent.
In terms of product, Anti-inflammatory Drugs is the largest segment, with a share over 50%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
LP Information, Inc. (LPI) ' newest research report, the “Dry Eye Syndrome Industry Forecast” looks at past sales and reviews total world Dry Eye Syndrome sales in 2024, providing a comprehensive analysis by region and market sector of projected Dry Eye Syndrome sales for 2025 through 2031. With Dry Eye Syndrome sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dry Eye Syndrome industry.
This Insight Report provides a comprehensive analysis of the global Dry Eye Syndrome landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dry Eye Syndrome portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dry Eye Syndrome market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dry Eye Syndrome and breaks down the forecast by Type, by Distribution Channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dry Eye Syndrome.
This report presents a comprehensive overview, market shares, and growth opportunities of Dry Eye Syndrome market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Artificial Tears
Anti-inflammatory Drugs
Others
Segmentation by Distribution Channel:
Hospital
Retail Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Allergan
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group
Key Questions Addressed in this Report
What is the 10-year outlook for the global Dry Eye Syndrome market?
What factors are driving Dry Eye Syndrome market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dry Eye Syndrome market opportunities vary by end market size?
How does Dry Eye Syndrome break out by Type, by Distribution Channel?
Please note: The report will take approximately 2 business days to prepare and deliver.